Identificador persistente para citar o vincular este elemento: https://accedacris.ulpgc.es/handle/10553/141746
Título: Automated Clinical Dosimetry Planning of Dense Lattice Radiation Therapy
Autores/as: Macías Verde, David Armando 
Burgos-Burgos, Javier
Lara, Pedro C.
Clasificación UNESCO: 32 Ciencias médicas
320101 Oncología
320111 Radiología
Palabras clave: Phase-I Trial
Lite Sabr M1
Radiotherapy
Lattice Radiation Radiotherapy
Lrt, et al.
Fecha de publicación: 2025
Publicación seriada: Cancers (Basel) 
Resumen: Background: Patients bearing large-volume, bulky primary or relapsed tumors, are usually referred to palliative low-dose radiotherapy with very poor results. Lattice Radiation Therapy (LRT) is able to produce a high number of high-dose foci or vortexes (multiple SBRT treatments), separated by low-dose zones (valleys). Treatment planning on vortex placing, valley definition, and dose administered depends on individual decisions of the treating team. The aim of our study is to assess for the first time the possibility of a dense fractionated LRT within the target volume. Methods: A total of 22 treatments in 20 patients were performed in the frame of a prospective observational study of fractionated LRT ongoing in our institution. According to our aim of achieving dense LRT, no GTV contraction was considered to create the LRTV (GTV is equal to LRTV). The vortexes were segmented as 1 cm diameter at a 1.5 cm vortex-to-vortex distance. Dose prescription to the vortexes per fraction was 12 Gy. Results: The vortex/LRTV ratio was 7.38 +/- 2.13% (3.4-10.40%, median 7.60%). Mean dose to the vortex volume was 11.90 +/- 0.09 Gy (11.70-12.10 Gy, median 11.90 Gy). Mean dose administered to the valley volume was 8.29 +/- 0.70 (7.05-9.51 Gy, median 8.29 Gy). Valley/vortex (peak) dose ratio (VPDR) was 69.40 +/- 6.02% (59.00-79.80%, median 69.70%). The mean peripheral tumor dose was 5.11 +/- 0.8710 Gy (3.16-6.78 Gy, median 5.18 Gy). Conclusions: Our dense LRT schedule fulfilled most of the recommended guidelines for LRT, increasing the high dose points without risking the dose to the surrounding tissues. Further analysis of feasibility and safety are needed to secure the clinical relevance of our proposed protocol.
URI: https://accedacris.ulpgc.es/handle/10553/141746
ISSN: 2072-6694
DOI: 10.3390/cancers17122048
Fuente: Cancers, [ISSN 2072-6694] v. 17 (12), (Junio 2025)
Colección:Artículos
Vista completa

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.